Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AmgenCHIX:AMGD 79 Future 3-5Y EPS without NRI Growth Rate is 5.54 as of Aug. 28, 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 79/100 and a GF Value™ of €302.69. The stock has 8 warning signs investors should review. Among 231 Drug Manufacturers companies, Amgen ranks worse than 92.21% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Amgen's Future 3-5Y EPS without NRI Growth Rate is 5.54.
Amgen (CHIX:AMGd) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Amgen Future 3-5Y EPS without NRI Growth Rate Related Terms
CHIX:AMGD vs GILD, PFE, BMY: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Amgen's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Amgen's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 5.54 mean?
Amgen (CHIX:AMGD) has a Future 3-5Y EPS without NRI Growth Rate of 5.54 as of Aug. 28, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Amgen and its competitors. According to the industry distribution chart, Amgen ranks #213 out of 231 companies in the Drug Manufacturers industry, placing it in the top 92.2%.
Is Amgen's Future 3-5Y EPS without NRI Growth Rate too high?
Amgen's current Future 3-5Y EPS without NRI Growth Rate is 5.54. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 16.57. Amgen's value of 5.54 is 66.6% below this industry median. Based on the distribution chart, Amgen ranks #213 out of 231 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amgen has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Amgen's Future 3-5Y EPS without NRI Growth Rate compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #213 out of 231 companies for Future 3-5Y EPS without NRI Growth Rate. This places Amgen in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 16.57. Amgen's value of 5.54 is 66.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 16.57, based on 231 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current Future 3-5Y EPS without NRI Growth Rate of 5.54 is 66.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Amgen and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 16.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Future 3-5Y EPS without NRI Growth Rate is 5.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Amgen (CHIX:AMGD) has a current Future 3-5Y EPS without NRI Growth Rate of 5.54. The stock's GF Value™ is €302.69, compared to a current price of €362.00 — trading 19.6% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 5.54 and 66.6% below the Drug Manufacturers industry median of 16.57. Amgen's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Future 3-5Y EPS without NRI Growth Rate is 5.54 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of €362.00 is trading 19.6% above its estimated GF Value™ of €302.69.
Key valuation signals for CHIX:AMGD:
Future 3-5Y EPS without NRI Growth Rate: 5.54
GF Value™: €302.69 vs. price of €362.00 (19.6% above fair value)
Industry Position: 66.6% below the Drug Manufacturers median (#213 of 231)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
79GF Score
Get the complete analysis for CHIX:AMGD
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
